Iris-Melanie
Noebauer-Huhmann1, Pavol Szomolanyi1,2, Claudia
Kronnerwetter1, Siegfried Trattnig1
1MR Centre - High field MR, Department
of Radiology, Medical University of Vienna, Vienna, Austria; 2Department
of Imaging Methods, Institute of Measurement Science, Slovak Academy of
Sciences, Bratislava, Slovakia
It
is well known that the effect of MR contrast agents is influenced by the
magnetic field strength. The aim of the study was to compare the diagnostic
efficacy of a Gadolinium-based MRI contrast agent (gadobenate dimeglumine) in
primary brain tumors at 7Tesla versus 3Tesla. Post contrast MP-RAGE sequences
were evaluated by region of interest measurements. At 7Tesla, the
tumor-to-brain-contrast after gadolinium administration was significantly
higher (91.4) than at 3Tesla (37.3). Further studies will show if the higher
tumor-to-brain-contrast post gadolinium administration at 7Tesla may be
beneficial for tumors with minor contrast agent accumulation, or allow for a
dose reduction.